Teva Pharmaceutical Industries Limited Sponsored ADR
(NYSE: TEVA)

Teva Pharmaceutical Industries Ltd (Teva) is an Israel-based pharmaceutical and drug company. It develops, produces and markets generic drugs in all treatment categories. The Company has a pharmaceutical business, whose principal products include Copaxone and Azilect. Teva�s active pharmaceutical ingredient (API) business provides vertical integration to Teva�s own pharmaceutical production. The Company�s global operations are conducted from North and Latin America to Europe and Asia. Teva operates a number of subsidiaries in such countries as Canada, Croatia, the Czech Republic, France, Germany, Hungary, Ireland, Israel, Japan, Poland, the Russian Federation, Spain, the Netherlands, the United Kingdom and the United States. In February 2014, the Company's subsidiary, Train Merger Sub, Inc, fully acquired NuPathe Inc. In July 2014, it acquired Labrys.

36.030 -

-0.220 (-0.61%)
Range 36.030 - 36.030   (-%)
Open 36.030
Previous Close 36.250
Bid Price 35.880
Bid Volume 100
Ask Price 35.980
Ask Volume 110
Volume 17,053
Value 49,063
Remark -
Delayed prices. Updated at 14 May 2026 21:20.
Data powered by
View All Events

About Teva Pharmaceutical Inds ADR

Teva Pharmaceutical Industries Ltd (Teva) is an Israel-based pharmaceutical and drug company. It develops, produces and markets generic drugs in all treatment categories. The Company has a pharmaceutical business, whose principal products include Copaxone and Azilect. Teva�s active pharmaceutical ingredient (API) business provides vertical integration to Teva�s own pharmaceutical production. The Company�s global operations are conducted from North and Latin America to Europe and Asia. Teva operates a number of subsidiaries in such countries as Canada, Croatia, the Czech Republic, France, Germany, Hungary, Ireland, Israel, Japan, Poland, the Russian Federation, Spain, the Netherlands, the United Kingdom and the United States. In February 2014, the Company's subsidiary, Train Merger Sub, Inc, fully acquired NuPathe Inc. In July 2014, it acquired Labrys.

Loading Chart...

Please login to view stock data and analysis